Skip to main content
EuroAPI logo

EuroAPI - Investor Relations & Filings

Listed IPO May 2022
Ticker · EAPI ISIN · FR0014008VX5 LEI · 9695002FT7GGI3CKKJ14 PA Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2024-06-26 Earnings Release
Country FR France
Listing PA EAPI · 7 venues

Key figures FY2025

Period ended 2025-12-31 · EUR
Headline annual figures for EuroAPI, fiscal year 2025, reported in EUR, with the source filing for each figure.
Total Revenues EUR 848.20M per the Earnings Release filed 2026-03-03
Net Income EUR -211.20M per the Earnings Release filed 2026-03-03
Total Assets EUR 1.30B per the Earnings Release filed 2026-03-03
Total Equity EUR 788.00M per the Earnings Release filed 2026-03-03
Cash from Ops EUR 128.50M per the Earnings Release filed 2026-03-03

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About EuroAPI

https://www.euroapi.com/en

EuroAPI is a developer and manufacturer of Active Pharmaceutical Ingredients (APIs), focusing on small and complex molecules. The company's business is centered on two main activities: offering API solutions from its large portfolio and providing Contract Development and Manufacturing Organization (CDMO) services. The product portfolio contains over 200 ingredients, with expertise in categories such as opiates and controlled substances, prostaglandins, corticoids, hormones, anti-infectives, and Vitamin B12. As a CDMO, EuroAPI provides services for complex chemistry, including small molecule synthesis, microbial fermentation, particle engineering (micronization and spray drying), and the development of lipids and tides like oligonucleotides, serving a global customer base.

Recent filings

Filing Released Lang Actions
EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth1
Earnings Release Classification · 98% confidence The document is explicitly titled "**Press Release**" and begins by announcing strategic updates, financial targets (EBITDA, CAPEX), financing agreements (Sanofi investment, RCF amendment), and revised guidance for the full year 2024. This structure—announcing key results, strategic plans (FOCUS-27), and forward-looking guidance immediately following the period end or as a major update—is characteristic of an Earnings Release (ER). It provides key highlights and outlook rather than the comprehensive, detailed financial statements found in an Interim Report (IR) or Annual Report (10-K). The document is not a transcript (CT), a formal audit report (AR), or a proxy statement (PSI). Since it is a full announcement of results and outlook, it fits best as an Earnings Release (ER). FY 2024
2024-06-26 English
EUROAPI et Priothera signent un accord de CDMO pour un projet en oncologie
Regulatory Filings Classification · 100% confidence The document is a press release ("Communiqué de presse") dated June 18, 2024, announcing a five-year Contract Development and Manufacturing Organization (CDMO) agreement between EUROAPI and Priothera regarding an oncology molecule (mocravimod). This type of announcement, detailing a significant business partnership, contract signing, or strategic development, does not fit neatly into the specific financial reporting categories like 10-K, ER, or IR. It is a general corporate announcement. Since it is not a report itself (like an Annual Report or Interim Report) but a specific business development announcement, and it doesn't fit categories like M&A (TAR) or Capital Change (CAP), the most appropriate general category for significant, non-standard corporate news is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory/corporate announcements not covered elsewhere.
2024-06-18 French
EUROAPI and Priothera enter into CDMO collaboration to advance oncology project
Regulatory Filings Classification · 100% confidence The document is explicitly titled "Press Release" and announces a specific business event: a 5-year Contract Development and Manufacturing Organization (CDMO) agreement between EUROAPI and Priothera regarding an oncology project. This type of announcement, detailing a strategic partnership or business development, does not fit neatly into the defined categories like 10-K (Annual Report), ER (Earnings Release), or CT (Call Transcript). It is a general corporate announcement. Since it is not a formal regulatory filing like a 10-K or a specific report like an AR or IR, and it doesn't relate to dividends, management changes, or shareholder votes, the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous corporate announcements that are not covered by more specific codes.
2024-06-18 English
Information marché  Financement du projet de transformation FOCUS-27
Capital/Financing Update Classification · 99% confidence The document is a press release ("Communiqué de presse") dated June 6, 2024, announcing that EUROAPI has decided to use an *ad hoc* agent to assist in discussions regarding the medium and long-term financing of its strategic transformation project (FOCUS-27). This announcement concerns fundraising, financing discussions, and capital structure strategy. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it is a press release, its core subject matter is financing, making CAP more specific than the general 'RPA' or 'RNS'. The document length (4170 chars) is short, but the content is a direct announcement about a financing action (engaging an advisor for financing discussions), not just announcing the publication of a separate, detailed report.
2024-06-06 French
Market update : FOCUS-27 transformation project financing
Capital/Financing Update Classification · 99% confidence The document is explicitly titled "Press release" and discusses the company's decision to appoint a *mandataire ad hoc* to assist in discussions regarding the financing of its 'FOCUS-27 strategic transformation project'. This announcement concerns fundraising and capital structure activities, specifically related to project financing. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it is a press release, the core subject matter is financing, making CAP more specific than the general 'RPA' or 'RNS'. The document length (3862 chars) is short, but the content is a direct announcement of a financing action, not just an announcement *about* a report.
2024-06-06 English
EUROAPI franchit une étape majeure du PIIEC Santé avec la notification officielle de la Commission européenne
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces a significant corporate event: EUROAPI receiving official notification from the European Commission regarding its selection for funding under the PIIEC Health project ('Med4Cure'). This announcement details strategic R&D programs, funding implications, and includes forward-looking statements and contact information typical of a public relations release regarding a major business development. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed financial report (IR). Since it is a press release announcing a major development (funding/strategic partnership), it fits best under the general category for regulatory announcements or significant corporate news that doesn't fit a more specific financial report type. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, non-financial-statement press release about a strategic milestone, although 'Capital/Financing Update' (CAP) is also plausible due to the funding aspect. However, RNS is often used for general corporate news releases that are regulatory in nature but not strictly financial reporting. Given the nature of the announcement (EU funding approval), it is a significant corporate event announcement, which often falls under RNS if a more specific category like 'TAR' (M&A) or 'CAP' (Financing) isn't a perfect fit. Since this is about receiving public funding for R&D projects, 'CAP' (Capital/Financing Update) is a strong candidate, but RNS covers general regulatory announcements. I will lean towards RNS as it is a broad announcement of a regulatory/governmental decision impacting the company, which is a common use case for RNS when other categories are too narrow. Upon review, the core of the news is securing public funding for strategic projects, which aligns closely with 'Capital/Financing Update' (CAP). However, RNS is the designated fallback for general regulatory announcements. Since this is a press release announcing a regulatory/governmental decision, RNS is the safest general classification for non-standard reports. I will classify it as RNS.
2024-06-06 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.